K36 Therapeutics Receives $70M Series B Financing to Develop KTX-1001 to Treat Multiple Myeloma
Shots:
- The round was led by Nextech Invest, BMS, and other undisclosed investors along with all existing investors incl. Atlas Venture, F-Prime Capital, and Eight Roads Ventures
- The fund will be utilized to develop the ongoing dose escalation P-I study evaluating the safety tolerability, and efficacy of KTX-1001 + SoC and the expansion of KTX-1001 into other hematological and solid tumor indications
- KTX-1001 is an orally administered small molecules, H3K36 methyltransferase MMSET inhibitor being developed to treat r/r multiple myeloma patients with the genetic translocation t(4;14)
Ref: PRNewswire | Image: K36 Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
